Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
- Check41 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check56 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check63 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check77 days agoChange DetectedNew additions include several important dates and the introduction of the Pembrolizumab Biosimilar RPH-075, while multiple previous update dates have been removed.SummaryDifference0.6%
Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.